SCHEMBL26812978

SCHEMBL26812978

O=S(=O)(Nc1nc(Oc2ccccc2)cc(-c2ccccc2)n1)c1cccs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ MAPT P10636 3/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ HSPD1 P10809 1/20 0.45
▸ PTPN2 P17706 1/20 0.45
▸ PTPN5 P54829 1/20 0.45
▸ HSPE1 P61604 1/20 0.45
▸ USP2 O75604 2/20 0.45
▸ USP8 P40818 2/20 0.45
▸ HTT P42858 2/20 0.44
▸ KDM1A O60341 1/20 0.44
▸ PTGS2 P35354 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ KDM4E B2RXH2 4/20 0.43
▸ ALDH1A1 P00352 3/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ TNF P01375 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26812942 0.84 MAPK1 (0.47) MAPK1TDP1MAPTPTGS2ALDH1A1
SCHEMBL26806813 0.83 MAPT (0.61) MAPK1TDP1MAPTHTTKDM4E
SCHEMBL26812947 0.82 TDP1 (0.47) MAPK1TDP1MAPTHTTALDH1A1
SCHEMBL26813005 0.81 MAPT (0.56) MAPK1TDP1MAPTHTTKDM4E
SCHEMBL26812935 0.81 MAPT (0.50) MAPK1TDP1MAPTHTTKDM1A
SCHEMBL26812853 0.80 MAPK1 (0.45) MAPK1TDP1MAPTHTTPTGS2
SCHEMBL26812825 0.79 TDP1 (0.51) MAPK1TDP1MAPTKDM4EALDH1A1
SCHEMBL26810944 0.79 MAPT (0.53) MAPK1TDP1MAPTHTTKDM4E
SCHEMBL24310173 0.78 MAPT (0.77) MAPK1TDP1MAPTJAK2HTT
SCHEMBL24310225 0.78 MAPT (0.52) MAPK1TDP1MAPTPTPN2PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B MAPK1 3810/4885TDP1 4534/4885MAPT 4864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback